Business context and reporting period
Filing identity: The supplied filing is Sigma Labs, Inc.’s Form 10-K, not a Nexttrip, Inc. filing. It covers the fiscal year ended December 31, 2019, rather than a standalone fourth quarter; the text does not provide clear Q4-only financial results.
Sigma develops PrintRite3D software and related products for in-process quality assurance in metal additive manufacturing. In 2019 it focused on test-and-evaluation programs with prospective customers and commercialization of version 5.0. Financial statement share amounts reflect the 1-for-10 reverse split effective February 27, 2020.
Financial performance and liquidity
| Metric | FY 2019 | FY 2018 |
|---|---|---|
| Revenue | $402,446 | $388,574 |
| Cost of revenue | $574,301 | $270,107 |
| Gross profit (loss) | $(171,855) | $118,467 |
| Operating expenses | $6,211,830 | $5,687,271 |
| Operating loss | $(6,383,685) | $(5,568,804) |
| Net loss | $(6,320,849) | $(5,574,163) |
| Operating cash flow | $(5,514,805) | $(3,762,971) |
Revenue increased about 3.6%, but gross margin fell to approximately negative 42.7%, from positive 30.5%, as cost of revenue rose substantially. Net loss widened about 13.4%. No income tax provision was recorded. The filing reports no long-term liabilities; year-end current liabilities included a $50,000 convertible note payable, which was repaid January 31, 2020 for $56,458 including interest and a late fee.
At December 31, 2019, cash was $86,919, working capital was negative $98,315, total assets were $1,691,468, and stockholders’ equity was $652,249. Cash declined from $1,279,782 a year earlier. Cash used in investing activities was $85,798; financing provided $4,407,740. The company had no credit line. January 2020 private placements generated approximately $1.71 million net proceeds. Management said funds were sufficient through the end of Q1 2020 and anticipated potential 2020 contracts, while acknowledging financing beyond that period might be needed.
Changes versus prior year
- Revenue rose modestly, driven mainly by $145,097 in increased PrintRite3D 5.0 system sales; declines in contract additive-manufacturing services and government program work partly offset the increase.
- Cost of revenue increased $304,194, attributed chiefly to system sales and travel and labor for test-and-evaluation programs.
- Operating expenses rose $524,559. Salaries and benefits, R&D, professional fees, and office expenses increased; stock-based compensation declined by $348,292.
- Operating cash use increased by $1,751,834. Management cited the larger net loss, increased inventory and prepaid expenses, and lower noncash stock compensation as contributing factors.
- Year-end inventory increased to $598,718 from $240,086, while accounts payable increased to $727,114 from $217,488.
Outlook, risks and unusual items
Management’s stated 2020 priority was converting 2019 testing into customer purchases and OEM licenses. RTE results were described as consistently favorable with no product failures, but completion took longer than expected because of customer-site operational issues. The filing provides no quantified revenue or profit guidance and gives no assurance that tests will translate into commercial orders.
Key commercial developments included Baker Hughes ordering a second test phase, ongoing programs with a major service provider and OEM, and Airbus testing. A March 2020 binding joint sales agreement with Materialise followed a prior non-binding MOU. These events occurred after year-end and are not 2019 revenue results.
Major risks include recurring losses, limited revenue, substantial cash burn and dependence on further financing; potential dilution from preferred stock and warrants; and Nasdaq’s requirement that the company evidence compliance with the $2.5 million stockholders’ equity threshold by June 30, 2020. The Series D preferred financing carries a 9% annual dividend payable in kind and conversion terms that may create significant dilution; the filing estimates up to 6,280,111 shares could be issued under specified conversion and warrant-exercise assumptions. Failure to meet preferred-stock conditions can also trigger redemption at a 125% premium. The company also cited commercialization, customer concentration, intellectual-property, execution, and coronavirus-related risks. Management reported disclosure controls and internal control over financial reporting effective at December 31, 2019; the auditor did not attest to internal-control effectiveness.
Other notable items: the company reported $51,877 in state incentives in 2019, no active government contracts as of March 2020, and no pending legal proceedings. It reported customer concentration, with four customers each contributing more than 10% of 2019 revenue; two customers together represented all year-end accounts receivable.
Investor verification checklist
- Confirm the issuer: this filing identifies Sigma Labs, Inc. (SGLB), not Nexttrip, Inc.
- Review subsequent cash use, contract receipts, and financing needs after the January 2020 placement and stated Q1 cash runway.
- Track Nasdaq equity-compliance status and any resulting listing action.
- Assess preferred-stock conversions, warrant exercises, potential redemption obligations, and resulting dilution.
- Verify whether RTE programs converted into recurring software sales, licenses, or follow-on orders, and whether customer concentration changed.
- Reconcile the annual results with any separate quarterly filing if Q4-specific performance is required.